[18F]Olaparib PET Imaging for Non-Invasive PARP Activity Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PARP inhibitors face challenges such as resistance, poor tumor penetration, and heterogeneity in PARP expression due to genomic instability, making it difficult to effectively target and monitor PARP enzyme activity in tumors, especially in invasive procedures like biopsies.
Innovation Solution
Development of a direct 18F-radiolabeled analogue of olaparib, [18F]olaparib, through copper-mediated 18F-fluorodeboronation using an N-[2-(trialkylsilyl)ethoxy]methyl protecting group, enabling non-invasive PET imaging for PARP enzyme distribution and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional PARP inhibitors are used, then PARP enzyme activity can be inhibited, but resistance develops and tumor penetration is poor
Solution Approach 1:
The patent modifies the chemical structure of olaparib by introducing a radiolabel (changing physical parameters) and creating a prodrug formulation (changing chemical parameters). The prodrug contains a leaving group that is displaced by nucleophiles in tumor cells, releasing the active PARP inhibitor. This structural parameter change enables both improved tumor penetration through the prodrug form and maintained PARP inhibition activity after activation.
Solution Approach 2:
The patent uses a prodrug as an intermediary substance that facilitates the delivery of the active PARP inhibitor to tumor cells. The prodrug formulation acts as a carrier that can penetrate tumor tissue more effectively than the active drug alone, then converts to the active form intracellularly through nucleophilic displacement of the leaving group. This intermediary approach resolves the contradiction between penetration capability and inhibition effectiveness.
2Measurement precision
If biopsies are performed to monitor PARP expression, then accurate measurement is achieved, but the procedure is invasive and complex
Solution Approach 1:
The patent replaces the mechanical biopsy procedure with a radiolabelled PET imaging approach. By incorporating a radiolabel into the PARP inhibitor molecule, the system enables non-invasive detection of PARP expression and drug uptake in tumors through positron emission tomography. This substitution eliminates the need for invasive tissue sampling while maintaining the ability to measure PARP-related parameters with high precision.
Solution Approach 2:
The patent introduces a radiolabel that emits detectable signals (analogous to color changes in detection) to enable visualization of PARP inhibitor distribution and binding. The radiolabel acts as a detectable marker that allows real-time monitoring of drug uptake and PARP enzyme activity in vivo, replacing the need for physical tissue removal and microscopic analysis.
3Ease of operation
If radiolabelled compounds are synthesized, then non-invasive imaging is enabled, but the synthesis process becomes more complex
Solution Approach 1:
The patent segments the synthesis process into two independent stages: first, synthesis of the radiolabelled prodrug precursor with the leaving group attached; second, conversion to the active PARP inhibitor form in the target organism. This segmentation allows the complex radiolabeling chemistry to be performed separately from the biological activation step, simplifying the overall process by enabling modular synthesis and reducing the complexity of in vivo application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
[18F]olaparib allows for accurate, non-invasive monitoring of PARP enzyme activity and tumor imaging, improving patient selection, treatment evaluation, and optimizing PARP inhibitor use by determining drug uptake and biological effects in vivo.
Implementation Method 1
treating an organoboron compound of formula (II) with 18F− and a copper compound
Implementation Method 2
direct 18F-radiolabeled analogue of olaparib, [18F]olaparib, enabling non-invasive PET imaging
Data Source
AI summary
The present invention relates to radiolabelled olaparib and in particular [18F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.